Impact of HER2 Overexpression and Coexpression of Hormonal Receptors on Pathological Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

被引：0
|
作者：
Moscoso, Louis [1 ]
Ruiz-Merino, Guadalupe
Huayna, Lourdes Salazar [1 ]
Iborra-Lacal, Emma
de Romani, Santiago Escriva [2 ]
Jimenez-Lucas, Maria
Raber, Christian Siso [1 ]
Cabezas-Herrera, Juan
Peg, Vicente [1 ]
Ramon Y Cajal, Santiago [3 ]
Pinero-Madrona, Antonio
机构：
[1] Hosp Univ Vall dHebron, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
LABORATORY INVESTIGATION | 2022年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
152
引用
收藏
页码：168 / 169
页数：2
相关论文
共 50 条
  • [31] Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer
    Guarneri, Valentina
    Barbieri, Elena
    Piacentini, Federico
    Dieci, Maria Vittoria
    Omarini, Claudia
    Ficarra, Guido
    Bettelli, Stefania Raffaella
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer
    Ferraro, Emanuela
    Safonov, Anton
    Wen, Hanna Y.
    Brogi, Edi
    Gonan, Mithat
    Barrio, Andrea V.
    Razavi, Pedram
    Chandarlapaty, Sarat
    Modi, Shanu
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2022, 82 (04)
  • [33] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    Mette S. van Ramshorst
    Claudette E. Loo
    Emilie J. Groen
    Gonneke H. Winter-Warnars
    Jelle Wesseling
    Frederieke van Duijnhoven
    Marie-Jeanne T. Vrancken Peeters
    Gabe S. Sonke
    Breast Cancer Research and Treatment, 2017, 164 : 99 - 106
  • [34] MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy
    van Ramshorst, Mette S.
    Loo, Claudette E.
    Groen, Emilie J.
    Winter-Warnars, Gonneke H.
    Wesseling, Jelle
    van Duijnhoven, Frederieke
    Peeters, Marie-Jeanne T. Vrancken
    Sonke, Gabe S.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 99 - 106
  • [35] HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
    Lillemoe, Tamera J.
    Rendi, Mara
    Tsai, Michaela L.
    Knaack, Monica
    Yarosh, Rina
    Grimm, Erin
    Susnik, Barbara
    Krueger, Janet
    Olet, Susan
    Swenson, Karen K.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2021, 2021
  • [36] Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
    Omarini, Claudia
    Bettelli, Stefania
    Manfredini, Samantha
    Barbolini, Monica
    Isca, Chrystel
    Cortesi, Giulia
    Maiorana, Antonino
    Tazzioli, Giovanni
    Dominici, Massimo
    Piacentini, Federico
    TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
  • [37] Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
    Heidy Cedeño
    Rafael Araúz
    Fernando Cebamanos
    Idalmis de Torraza
    Ana Porcell
    BMC Cancer, 7 (Suppl 1)
  • [38] Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
    Takada, Masahiro
    Sugimoto, Masahiro
    Masuda, Norikazu
    Iwata, Hiroji
    Kuroi, Katsumasa
    Yamashiro, Hiroyasu
    Ohno, Shinji
    Ishiguro, Hiroshi
    Inamoto, Takashi
    Toi, Masakazu
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [39] Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
    Jia, Miaomiao
    Yang, Haibo
    Pan, Lihui
    Gao, Jinnan
    Guo, Fan
    BREAST JOURNAL, 2024, 2024
  • [40] Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer
    Jung, S.
    Jeon, C. W.
    Choi, J.
    Hyun, D.
    Lee, H.
    Kwon, K.
    Yoon, H.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S59 - S59
12345